TestCard has developed a healthcare technology platform that converts a typical smartphone into a clinical‑grade scanner to accurately read lateral flow and colorimetric dipstick tests. The company’s technology underpins consumer-facing and clinical workflows, and its first product was a UTI test‑and‑treat service distributed through extensive retail partnerships. In 2021 it partnered with Superdrug Online Doctor, Welldricks, Chemist4U, Zava, Numark, Alphega and Amazon, and in Q1 2022 it launched with Rowlands and Lloyds Online Doctor. TestCard also launched its ClearScreen Covid‑19 antigen testing solution into the NHS in partnership with Guy’s and St Thomas’ Foundation Trust, improving traceability and reducing admin time. Led by CEO Chris Craig‑Wood, the company plans to commercialize its existing product suite, launch new tests for diabetes, pregnancy, CKD and flu, and to continue investing in its technology and IP. TestCard is pursuing US expansion in early 2023 and is working on FDA approval for its first product. TestCard develops paper "postcard" urine test strips read by a smartphone app to deliver at-home diagnostics for pregnancy, urinary tract infections, blood glucose and illegal drugs. The app scans a QR code to identify the test, times development, and uses algorithms developed in Plovdiv, Bulgaria to read color changes; Roche reportedly confirmed the app's accuracy. Founded in 2017, the company has filed several patents and employs eight full-time people. TestCard plans a UK launch this summer with the postcard priced at £5 and a free app, and has partnerships with NHS London to reach 2.5M residents and with Aetna for diabetes rollouts in India, Thailand and the Philippines. The company aims to expand in emerging markets, move manufacturing to Mumbai to lower costs, and expects to enter the US in 2020. TestCard is pursuing CE marking for medical devices and recently raised additional funding to continue product development. TestCard develops an at-home urine testing service that pairs a non-invasive urine test kit embedded into a postcard with a mobile application that turns a smartphone camera into a clinical-grade scanner. Its initial applications include detection of urinary tract infections (UTIs) and pregnancy testing that provides a specific due date for positive results and an optimal date to try to conceive for negatives. The company says its product pipeline will expand to prostate health screening and monitoring of conditions like diabetes and kidney disease. TestCard is led by co-founders Luke Heron (CEO) and Dr. Andrew Botham (CSO) with George Sutherland as Chairman. The company completed a $1.7M seed financing and intends to use the funds to launch and carry out an initial roll-out phase.

Total raised

$14M

Funding rounds

3

Latest round

Equity

Latest activity

Apr 2022